p53

Over half of all known cancers involve some mutation in p53, the so-called guardian of the cell. p53 is a tumor-suppressor which signals for cell death if DNA gets damaged.

Without p53, damaged DNA can lead to the unusual growths found in cancer tumors. When p53 breaks down and does not fold correctly, then DNA damage goes unchecked and mutations can proliferate. We have been studying specific domains of p53 in order to predict mutations relevant in cancer and to study known cancer-related mutants.

By Nephron (Own work) [CC BY-SA 3.0 or GFDL], via Wikimedia Commons
By Nephron (Own work) [CC BY-SA 3.0 or GFDL], via Wikimedia Commons
  • Results of a kinase study published

    The paper on the results of a kinase study conducted by Dr. Diwakar Shukla and his fellow researchers has been published. This kinase under investigation is c-src, which has been…

    Read more
  • Using Folding@home to understand the fundamental behavior of kinases

    FAH researchers Dr. Diwakar Shukla and Dr. Morgan Lawrenz have been using Folding@home to understand the fundamental behavior of kinases, key molecular targets in cancer.  A paper on these results…

    Read more
  • Assisting Chris Garcia’s lab with their work with Interleukin 2 (IL-2)

    We assisted Chris Garcia’s lab with their work with Interleukin 2 (IL-2), a protein which assists the immune system in fighting pathogens and cancer tumors. While injecting a patient with…

    Read more
  • Simulating forms of Pin1 WW domain

    We are simulating many forms of Pin1 WW domain, a protein implicated in some cancers and Alzheimer’s disease. Understanding the role of mutations on misfolding can have important biomedical consequences.

    Read more
  • Studying the folding of ubiquitin

    We’re studying the folding of ubiquitin, a small regulatory protein found in almost all cells in human body. It is part of a large regulatory system that labels other unneeded…

    Read more
  • Recent results presented at FAHcon 2012

    At FAHcon 2012, Dr. Xuhui Huang presented our recent results of the molecular mechanisms of gene transcription. Transcription is the first step in reading genomic DNA, and regulation of this…

    Read more
  • Dr. Peter Kasson applying work on viruses to cancer

    Dr. Peter Kasson has been applying his work on viruses to cancer, as many cancers are virus-associated.

    Read more
  • Anti-cancer strategy involving kinases

    Please see this blog post for Dr. John Chodera’s anti-cancer strategy involving kinases.

    Read more
  • Collaboration with the Nanomedicine Center for Protein Folding

    In collaboration with the Nanomedicine Center for Protein Folding, we have been using our methods to further push a chaperonin inhibitor. This next round will use new scoring functions from…

    Read more
  • New Protomol (Core B4) core to study enzyme in some kinds of cancer

    We’ve been using our new Protomol (Core B4) core to study the activation of src Kinase, an enzyme that is involved in the onset of some kinds of cancer.

    Read more
  • New software methods for the chaperonin inhibitor project

    Del has been involved in the development of new software methods (Ocker) for the chaperonin inhibitor project.

    Read more
  • Del has presented his plans to the NIH Nanomedicine center

    Del has presented his plans to the NIH Nanomedicine center with a very positive response. Planning for the lab side of this work has begun.

    Read more
  • Plans for fighting cancer with FAH

    Plans have started to take a new approach for using FAH to fight cancer: to develop novel chaperonin inhibitors. FAH researcher Del Lucent is taking the lead. See this blog…

    Read more
  • p53 presentation

    FAH researcher Dr. Lillian Chong presented her work on p53 at a lecture at several US Universities.

    Read more
  • p53: two sets of projects completed and two new papers for peer review

    Two new sets of projects have completed and two new papers are being readied for peer-reviewed publication.

    Read more
  • Interesting results from p53 projects

    We are getting some interesting results from recent new FAH p53 projects.

    Read more
  • Expanding p53

    We are expanding FAH’s p53 work to other related p53 systems

    Read more
  • First work on cancer

    Our first work on cancer has recently been published.

    Read more